Aniket Bankar, MD, discusses why rusfertide is considered a promising therapeutic approach for patients with polycythemia vera.

Investigators added more data to an analysis first published in 2020 and got the same result: ruxolitinib beats other ...

In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

Polycythemia vera can be treated with medical interventions and medication to reduce the effects of complications and improve life expectancy. Since there is no cure, disease surveillance and ...

Ropeginterferon alfa-2b (Ropeg) is approved for the treatment of adults with polycythemia vera (PV). This report aims to analyze the ethnic sensitivity of Ropeg for the treatment of PV, comparing the ...

Protagonist Therapeutics has 2 attractive late-stage pipeline assets, but commercialized sales will not begin until 2027.

Hence, just like low haemoglobin levels (less than 13.2 g/dL for men and 11.6 g/dL for women) necessitate medical ...

An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.

Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of ...

Image Source: Zacks Investment Research Incyte’s lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to ...

Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise ...

Read on to learn what doctors look for in a routine blood test and what’s considered a healthy PCV range for Male, Female and ...